Zahinoor Ismail, MD FRCPC, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada, discusses how to optimize the detection of prodromal Alzheimer’s disease (AD). This study utilized mild behavioral impairment (MBI), which is a syndrome/construct developed to identify pre-clinical and prodromal dementia using neuropsychiatric symptoms (NPS) to determine risk. MBI can be used as a beneficial tool to identify a group with greater risk for incident cognitive decline and dementia. For NPS to reach MBI criteria, they must be later-life emergent and persistent. To understand more about the relationship between MBI and AD pathology, ADNI (NCT00106899) and MEMENTO (NCT01926249) participants with mild cognitive impairment (MCI) were studied over a 4-year time frame. The study aimed to analyze differences in AD CSF biomarkers in the MBI, NPS (symptoms that don’t match MBI criteria), and no NPS groups. The MBI group was found to be associated with a worsening biomarker profile compared to the other two groups. This supports the use of MBI in dementia detection and prognostication, as the findings highlight the utility of applying the MBI criteria to MCI to improve the specificity for detection of prevalent AD and prediction of incident AD dementia. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
